In West Africa, Single-Dose Antibiotic Treats Vaginal Discharge as Effectively as Multiple-Dose Treatment

London, S.
December 2006
International Family Planning Perspectives;Dec2006, Vol. 32 Issue 4, p213
Academic Journal
The article presents information on a clinical trial conducted in West Africa, which tried to assess the effectiveness of a single-dose of antibiotics tinidazole and fluconazole in treating vaginal discharge. The trial found that the treatment with the single dose was as effective as a multiple-dose antibiotic treatment with metronidazole and vaginal clotrimazole. It was also observed that the treatment was effective on women infected with HIV.


Related Articles

  • Evaluation of the safety and efficacy of cystone liquid in the management of lower ureteric stones. Jeyaraman, R.; Mitra // Indian Journal of Urology;Supplement1, Vol. 24, pS49 

    It is a prospective randomized study to evaluate the safety and effectiveness of cystone liquid in the management of lower ureteric stones. Twenty five patients between the age 18 yrs and 65 yrs were included in the study. The stones were located in the lower ureter below the level of iliac...

  • Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose. Leil, T. A.; Feng, Y.; Zhang, L.; Paccaly, A.; Mohan, P.; Pfister, M. // Clinical Pharmacology & Therapeutics;Sep2010, Vol. 88 Issue 3, p375 

    A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial. The exposure–response models demonstrated that an increase in daily steady-state area under the plasma...

  • A Comparative Trial of a New Antidepressant, Fluoxetine. Levine, S.; Deo, A.; Mahadevan, K. // British Journal of Psychiatry;May87, Vol. 150, p653 

    This clinical trial of a new antidepressant, fluoxetine, shows it to be as effective as a standard tricyclic drug, imipramine. It is effective as a single daily dose and is free of any significant side-effects. It is less sedative and appears to cause fewer problems of weight increase. The three...

  • Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, Phase II, dose-ranging study.  // International Journal of Advances in Rheumatology;2011, Vol. 9 Issue 1, p29 

    In this article the authors comment on a study conducted by A. So, M. de Meulemeester, A. Pikhlak, and colleagues on the efficacy of canakinumab for treating acute gouty arthritis. The authors assert that the study discovered that 150 milligram (mg) canakinumab was more effective than 40 mg...

  • 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. Rosemurgy, Alexander; Luzardo, German; Cooper, Jennifer; Bowers, Carl; Zervos, Emmanuel; Bloomston, Mark; Al-Saadi, Sam; Carroll, Robert; Chheda, Hemant; Carey, Larry; Goldin, Steven; Grundy, Shane; Kudryk, Bruce; Zwiebel, Bruce; Black, Thomas; Briggs, John; Chervenick, Paul // Journal of Gastrointestinal Surgery;Apr2008, Vol. 12 Issue 4, p682 

    This prospective randomized trial was undertaken to determine the added efficacy of (32)P in treating locally advanced unresectable pancreatic cancer. Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil...

  • Collaborative Multidisciplinary Workshop Report: Clinical Antimicrobial Trials for Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Rosen, Henry; Muhlestein, Joseph B.; Bartlett, John; Chen, Shaw; Chikami, Gary; Corson, Marshall; Shah, P. K.; Gurfinkel, Enrique; Handsfield, Hunter; Jackson, Lisa; Knirsch, Charles; Kronmal, Richard; McCutchan, J. Allen; Shea, Steven // Journal of Infectious Diseases;6/15/2000 Supplement 3, Vol. 181, pS582 

    Evaluates the need for additional clinical antibiotic trials of a primary or secondary nature for the treatment of atherosclerotic heart disease and to suggest possible designs for future trials. Status of ongoing and already completed clinical trials; Limitations of the trials; Points to...

  • From the Bedside to the Bedside.'.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p7 

    This article deals with additional preliminary results reported by Mersana Therapeutics from a Phase 1 study of its lead development candidate XMT-1001 in patients with advanced solid tumors. 49 patients with refractory solid tumors served as subjects in this study. Particular focus is given to...

  • Brivudin: A Viewpoint by Gerd Gross. Gross, Gerd // Drugs;2004, Vol. 64 Issue 18, p2098 

    The oral antiviral agent brivudin is effective in the early treatment of acute herpes zoster in immunocompetent adults. The drug has high and selective activity against varicella-zoster virus (VZV). It has a markedly higher anti-VZV potency than other oral antiviral agents approved for the...

  • Phase I oncology trials incorporating patient choice of dose. Huson, L W // British Journal of Cancer;9/25/2012, Vol. 107 Issue 7, p1022 

    Background:Patients recruited in phase I oncology trials are often treated at doses lower than the maximum tolerated dose (MTD), and therefore may not receive the most efficacious dose available, despite their expectations to the contrary. This report investigates the consequences of allowing a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics